肝细胞MLKL非坏死性凋亡机制驱动肥胖相关MASLD-HCC进展
该研究利用长期西方饮食诱导的肝细胞特异性MLKL敲除小鼠MASLD-HCC模型,发现MLKL通过抑制MFN2、损害线粒体功能促进肿瘤增殖和干性,且不依赖坏死性凋亡;人类MLKL抑制剂NSA可抑制HepG2异种移植瘤生长,MLKL高表达与HCC总生存期较差相关。
要点
- 肝细胞MLKL在MASLD中升高但不激活坏死性凋亡,通过抑制MFN2损害线粒体功能促进HCC。
- MLKL敲除减少肿瘤数量、大小、发生率、多发性和增殖并降低干性。
- MLKL抑制剂NSA抑制HepG2异种移植瘤生长,MLKL高表达与HCC总生存期较差相关。
核心结论
- 肝细胞MLKL通过非坏死性凋亡机制(涉及MFN2抑制、线粒体功能受损及肿瘤增殖和干性增加)促进MASLD相关HCC,是潜在治疗靶点。
研究设计与样本
- 使用长期西方饮食诱导的MASLD-HCC模型,比较肝细胞特异性MLKL敲除小鼠与对照小鼠。
- 采用转录组分析、HCC细胞实验及HepG2异种移植瘤模型验证机制。
主要发现
- 西方饮食增加肝细胞MLKL蛋白表达但未检测到坏死性凋亡激活,提示非坏死性凋亡作用。
- MLKL缺失不改变西方饮食诱导的炎症、纤维化或肝损伤,但增加肝脏脂质积累、减少脂毒性脂质种类并保护线粒体功能。
- 西方饮食喂养的MlklHepKO小鼠肿瘤更少更小,发生率、多发性、增殖和干性均降低。
- 转录组分析显示MlklHepKO肝脏中线粒体氧化磷酸化通路上调。
- 西方饮食抑制线粒体融合蛋白及肿瘤抑制因子MFN2,MLKL缺失在翻译后水平恢复MFN2表达。
临床怎么用
- MLKL高表达可能提示MASLD相关HCC预后较差,但需进一步验证。
- MLKL抑制剂NSA在临床前模型中抑制HCC生长,支持MLKL作为治疗靶点的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of HCC, particularly in obesity, yet mechanisms linking hepatocyte dysfunction to tumorigenesis remain unclear. Mixed lineage kinase domain-like protein (MLKL), the effector of necroptosis, is elevated in MASLD, but its hepatocyte-intrinsic role in obesity-driven MASLD-HCC is unknown. APPROACH AND RESULTS: Using a long-term western diet (WD)-induced MASLD-HCC model in hepatocyte-specific MLKL knockout ( MlklHepKO ) mice, we defined MLKL's hepatocyte-intrinsic function. WD increased hepatocyte MLKL protein expression without detectable necroptosis activation, indicating a necroptosis-independent role. MLKL deficiency did not alter WD-induced inflammation, fibrosis, or liver injury but increased hepatic lipid accumulation while reducing lipotoxic lipid species and preserving mitochondrial function. WD-fed MlklHepKO mice developed fewer and smaller tumors with reduced incidence, multiplicity, proliferation, and stemness. Transcriptomic analysis revealed upregulation of mitochondrial oxidative phosphorylation pathways in MlklHepKO livers. WD suppressed the mitochondrial fusion protein and tumor suppressor mitofusin 2 (MFN2), whereas MLKL deficiency restored MFN2 expression post-translationally. In HCC cells, MLKL deletion reduced proliferation, improved mitochondrial respiration, and decreased glycolysis; these effects were reversed by MFN2 deletion. MLKL is localized to nuclear and mitochondrial compartments, consistent with organelle-intrinsic functions. The human MLKL inhibitor necrosulfonamide (NSA) suppressed HepG2 xenograft growth, and elevated MLKL expression in human HCC correlated with poorer overall survival. CONCLUSIONS: Hepatocyte MLKL promotes MASLD-associated HCC through a non-necroptotic mechanism involving MFN2 suppression, impaired mitochondrial function, and increased tumor proliferation and stemness. These findings identify MLKL as a potential therapeutic target in MASLD-associated HCC.
引用
- Ohene-Marfo P, Mohammed S, Jiang C, et al. Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD. Hepatology. 2026. PMID: 42549799. doi:10.1097/HEP.0000000000001830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。